Under the scheme of amalgamation for merger, subsidiaries such as PHL Capital Private Limited, Piramal Pharmaceutical Development Services Private Limited and Oxygen Bio Research Private Limited will merge with Piramal Enterprises Ltd.
"Since all the transferor companies are step down wholly owned subsidiaries of the company, no shares are proposed to be issued pursuant to the merger. This scheme is subject to requisite approvals, including under the Listing Agreement and by the hon’ble High Courts," company said in a statement.
More From This Section
Piramal Pharmaceutical Development Services Private Limited, is R&D arm, working under Piramal Healthcare. Oxygen Bio Research Pvt. Ltd is a contract research organisation (CRO) working on the synthetic drug discovery programme.
Piramal Capital is one of the group's finance arm. On Monday, shares of PEL were closed at Rs 554/1, up by 1.52%.